Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

ABSTRACT: OBJECTIVE:To study the safety and efficacy of the cholinesterase inhibitor donepezil in patients with Parkinson's disease (PD) and cognitive impairment. METHODS:This was a double blind, randomised and placebo controlled, crossover study in which 14 patients with PD and cognitive impairment received donepezil (5 or 10 mg per day) or matching placebo during two sequential periods lasting 10 weeks each. The primary outcome measures were the mini mental state examination (MMSE) score, the clinician's interview based impression of change plus caregiver input (CIBIC+) score, and the motor subscale of the unified Parkinson's disease rating scale (UPDRS). RESULTS:Two patients on donepezil (14%) dropped out after one and four weeks of the first treatment period because of peripheral cholinergic sid

SUBMITTER: Aarsland D 

PROVIDER: S-EPMC1737925 | biostudies-literature | 2002 Jun

REPOSITORIES: biostudies-literature